Zacks: Brokerages Anticipate CRISPR Therapeutics (CRSP) Will Announce Quarterly Sales of $2.45 Million

Brokerages predict that CRISPR Therapeutics (NASDAQ:CRSP) will announce sales of $2.45 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for CRISPR Therapeutics’ earnings, with estimates ranging from $500,000.00 to $4.40 million. CRISPR Therapeutics posted sales of $2.70 million during the same quarter last year, which suggests a negative year-over-year growth rate of 9.3%. The firm is expected to report its next quarterly earnings results on Thursday, May 10th.

According to Zacks, analysts expect that CRISPR Therapeutics will report full-year sales of $14.67 million for the current financial year, with estimates ranging from $2.00 million to $24.00 million. For the next year, analysts anticipate that the business will post sales of $91.10 million per share. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for CRISPR Therapeutics.

How to Become a New Pot Stock Millionaire

A number of analysts recently issued reports on CRSP shares. SunTrust Banks reissued a “buy” rating and set a $65.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, March 9th. Piper Jaffray reissued a “buy” rating and set a $22.75 price objective (down from $39.00) on shares of CRISPR Therapeutics in a research report on Wednesday, January 10th. BidaskClub raised CRISPR Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. Goldman Sachs started coverage on CRISPR Therapeutics in a research report on Friday, April 6th. They set a “buy” rating and a $86.00 price objective for the company. Finally, TheStreet raised CRISPR Therapeutics from a “d+” rating to a “c” rating in a research report on Friday, March 16th. Five equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $63.95.

Shares of NASDAQ:CRSP traded down $0.59 during midday trading on Monday, reaching $51.18. 1,053,276 shares of the company’s stock were exchanged, compared to its average volume of 1,143,479. The company has a market capitalization of $2,441.83, a price-to-earnings ratio of -29.93 and a beta of 3.53. CRISPR Therapeutics has a fifty-two week low of $13.50 and a fifty-two week high of $61.24.

In other CRISPR Therapeutics news, insider Tyler Dylan-Hyde sold 66,000 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $28.03, for a total value of $1,849,980.00. Following the completion of the transaction, the insider now directly owns 25,204 shares of the company’s stock, valued at approximately $706,468.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 39.98% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Creative Planning acquired a new position in CRISPR Therapeutics in the 4th quarter valued at about $243,000. Paloma Partners Management Co acquired a new position in CRISPR Therapeutics in the 4th quarter valued at about $290,000. D.A. Davidson & CO. acquired a new position in CRISPR Therapeutics in the 4th quarter valued at about $370,000. Bank of New York Mellon Corp acquired a new position in CRISPR Therapeutics in the 3rd quarter valued at about $288,000. Finally, Vanguard Group Inc. acquired a new position in CRISPR Therapeutics in the 2nd quarter valued at about $273,000. 26.50% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Anticipate CRISPR Therapeutics (CRSP) Will Announce Quarterly Sales of $2.45 Million” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/16/zacks-brokerages-anticipate-crispr-therapeutics-crsp-will-announce-quarterly-sales-of-2-45-million.html.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Get a free copy of the Zacks research report on CRISPR Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply